CAR-T Cell Therapy Development for Bladder Cancer

Inquiry

There is a persistent need for new and more effective treatments for bladder cancer. CAR-T cell therapy stands out as one of the most promising options. Alfa Cytology is committed to developing targeted CAR-T cell therapies specifically for bladder cancer.

Introduction to CAR-T Cell Therapy for Bladder Cancer

CAR-T (chimeric antigen receptor T cell) therapy represents a revolutionary advancement in bladder cancer treatment by harnessing the power of genetically modified T cells to attack cancer cells. This therapy involves modifying a patient's T cells to express chimeric antigen receptors (CARs) that recognize specific surface antigens on bladder cancer cells. CAR-T therapy is distinct in its ability to directly target surface antigens without relying on MHC presentation, making it a highly effective approach for cancers with known surface markers.

Fig.1 CAR-T cell therapy. (Morales, L., et al., 2021)

Our Services

Alfa Cytology is a leading preclinical contract research organization (CRO) specializing in bladder cancer research and therapy development. Our comprehensive CAR-T cell therapy development services aim to expedite the research and development process for bladder cancer immunotherapy.

Target Identification and Validation

Target Selection

We use advanced bioinformatics and genomics to help clients identify and select bladder cancer-specific antigens.

Target Validation

Conducting in vitro and in vivo experiments to validate the specificity and efficacy of the selected targets.

CAR-T Construct Design

CAR Design

Designing and constructing efficient CAR molecules, optimizing their structure to enhance anti-tumor activity.

Gene Editing

Employing cutting-edge gene editing technologies like CRISPR/Cas9 to improve the stability and functionality of CAR-T cells.

In Vitro Functional Assessment

Cytotoxicity Assays

Evaluating the cytotoxic activity of CAR-T cells to measure their ability to recognize, target, and destroy bladder cancer cells.

Proliferation and Persistence Testing

Assessing the proliferation capacity and persistence of CAR-T cells.

In Vivo Efficacy Evaluation

Animal Models

Using bladder cancer animal models, we rigorously evaluate the anti-tumor efficacy of CAR-T cells.

Safety Testing

Conducting safety and toxicology assessments to ensure the clinical safety of CAR-T cell therapy.

Process Development and Optimization

Manufacturing Process Development

Optimizing the expansion and production processes of CAR-T cells to ensure consistency and high quality in large-scaleproduction.

Quality Control

Establishing rigorous quality control systems to ensure quality and functionality.

Contact Us

To propel your CAR-T cell research forward, Alfa Cytology provides a wide array of tailored CAR-T development services. Our expertise spans from initial CAR design through rigorous cellular functional validation to scalable cell expansion protocols. Whether you're focusing on optimizing CAR constructs or need robust preclinical testing for bladder cancer therapies, our dedicated team is here to support your project. For more information on our specialized CAR-T cell therapy development for bladder cancer, we invite you to contact us today.

Reference

Morales, L., & Paramio, J. M. Cell Therapies in Bladder Cancer Management. International journal of molecular sciences, 2021, 22(6), 2818.

For research use only. Not intended for any clinical use.

Related Services

Solutions

Inquiry

* Name:

* Email:

Phone:

* Services:

Description:

* Please note that we are not a pharmacy or clinic, so we do not offer diagnostic and treatment services for patients.

* Tick to confirm the Research Use Only (RUO) statement.